The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: The OLCA study

Daikuhara, Hiroyuki; Kikuchi, Fumi; Ishida, Toshihiko

doi:10.1177/1479164112447310

Cited by 10 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, olmesartan plus azelnidipine enhanced cerebrovascular and renal protective effects by suppressing NADPH oxidase‐dependent oxidative stress (Rafiq et al, ) and showed antiatherogenic effects by suppressing oxidative stress and activating endothelial nitric oxide synthase (Noda et al, ). In a clinical study for type 2 diabetic hypertensive patients, the combination of olmesartan plus azelnidipine was more beneficial against BP morning surge, showed a greater decrease in heart rate, and improved glucose tolerance and microalbuminuria more than candesartan plus amlodipine therapy (Daikuhara et al, ). In the present study, the low‐dose (1 mg/kg each) combination of olmesartan plus azelnidipine showed a synergistic effect, compared with low‐dose (2 mg/kg) monotherapy, for decreasing spontaneous infarct volume by reducing oxidative stresses and inflammatory responses while imparting neurovascular protection (Figs.…”

Section: Discussionmentioning

confidence: 99%

Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke‐prone spontaneously hypertensive rats

Omote

Deguchi

Kono

et al. 2014

J of Neuroscience Research

View full text Add to dashboard Cite

An angiotensin 2 type 1 receptor blocker, olmesartan, and a calcium channel blocker, azelnidipine, possess not only an antihypertensive effect but also an antioxidative effect and other beneficial effects. In the present study, we examined the efficacy of olmesartan and azelnidipine monotherapy (2 mg/kg or 10 mg/kg each) and their combination therapy (1 mg/kg each) on stroke-prone spontaneously hypertensive rats (SHR-SP) in relation to oxidative stress, inflammation, and the neurovascular unit. In comparison with the vehicle group, body weight, regional cerebral blood flow, and motor function were preserved, whereas systolic blood pressure and diastolic blood pressure decreased in the five drug-treatment groups. Spontaneous infarct volume decreased with the low-dose combination of olmesartan plus azelnidipine and with the high-dose olmesartan, with a further decrease in the high-dose azelnidipine group. In addition, these drugs dose-dependently reduced oxidative stresses, proinflammatory molecules, and well-preserved components of the neurovascular unit. The low-dose combination of olmesartan plus azelnidipine showed a better effect than the low-dose olmesartan or azelnidipine monotherapy. The present study shows that the low-dose combination of olmesartan plus azelnidipine demonstrates a greater synergistic benefit than monotherapy with a low-dose of olmesartan or azelnidipine in SHR-SP for preventing spontaneous infarct volume, reducing oxidative stresses and proinflammatory molecules, and imparting neurovascular protection. In addition, a high-dose of olmesartan showed a greater benefit without the lowering of blood pressure, probably because of the antioxidative and anti-inflammatory effects. A high dose of azelnidipine showed the best benefit, probably because of the two effects mentioned above related to the lowering of blood pressure.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke‐prone spontaneously hypertensive rats

Omote

Deguchi

Kono

et al. 2014

J of Neuroscience Research

View full text Add to dashboard Cite

show abstract

“…This difference in the change in urinary albumin excretion is considered to reflect the sustained antihypertensive effect of olmesartan. Furthermore, we previously reported that olmesartan plus azelnidipine was more effective at lowering morning home BP and reducing urinary albumin than candesartan plus amlodipine in the combination of OLmesar tan and a CAlcium channel blocker (OLCA) study 17. We had thought that the improvement in microalbuminuria seemed to be partially attributed to the difference between calcium channel blockers.…”

Section: Discussionmentioning

confidence: 99%

Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study

Daikuhara¹,

Fukunaga²,

Ohshima³

2014

DDDT

Self Cite

View full text Add to dashboard Cite

PurposeThis open-label controlled study compared the therapeutic efficacy of three representative angiotensin II receptor blockers (ARBs) in hypertensive patients with type 2 diabetes attending a hospital outpatient clinic. The primary measure in this study was morning home blood pressure (BP).Patients and methodsTwo studies were done concurrently to investigate the effects of switching from two different ARBs to olmesartan. Patients prescribed candesartan (8 mg once daily in the morning) or telmisartan (40 mg once daily in the morning) for 16 weeks were switched to olmesartan (20 mg once daily in the morning) for 16 weeks. Then, they were switched back to candesartan (CO group) or telmisartan (TO group) for another 16 weeks.ResultsData from all patients in the CO group (n=165) and the TO group (n=152) were analyzed. Clinic and morning home BP and urinary albumin levels showed a significant decrease from baseline at 16 weeks after switching to olmesartan in both the CO and the TO group (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). In contrast, clinic BP, morning home BP, and urinary albumin were significantly increased again 16 weeks after switching back to candesartan or telmisartan (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). No subjects experienced an adverse reaction that required withdrawal from the study. No adverse reactions attributable to the study drugs were observed.ConclusionOlmesartan is a promising ARB for BP control in hypertensive type 2 diabetics.

show abstract

“…To determine which combination performed better, Daikuhara [71] conducted the OLCA study, which was an open-label randomized study aimed at untreated diabetic hypertensive patients. At the beginning, 300 patients were randomized to have either olmesartan (20 mg/day) or candesartan (8 mg/day), with 150 participants in each group.…”

Section: Methodsmentioning

confidence: 99%

Management of Hypertension Using Olmesartan Alone or in Combination

Zhang

et al. 2017

Cardiol Ther

View full text Add to dashboard Cite

Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.

show abstract

The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: The OLCA study

Cited by 10 publications

References 19 publications

Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke‐prone spontaneously hypertensive rats

Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke‐prone spontaneously hypertensive rats

Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study

Management of Hypertension Using Olmesartan Alone or in Combination

Contact Info

Product

Resources

About